SBF2-AS1: An oncogenic lncRNA in small-cell lung cancer |
| |
| Authors: | Youwei Zhang Yang Li Liang Han Peiying Zhang Sanyuan Sun |
| |
| Institution: | 1. Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, China;2. Department of Molecular Laboratory, Xuzhou Central Hospital, Xuzhou Medical University, Xuzhou, China |
| |
| Abstract: | The long noncoding RNAs (lncRNAs) SBF2 antisense RNA 1 (SBF2-AS1) was found to act as an oncogenic lncRNA in non–small-cell lung cancer (NSCLC), but the role of SBF2-AS1 in small-cell lung cancer (SCLC) was still unclear. The purpose of this study was to provide the clinical significance and biological function of SBF2-AS1 in SCLC. In our results, SBF2-AS1 was found to be upregulated in SCLC tissues compared with NSCLC tissues or adjacent normal lung tissues. Besides, SBF2-AS1 expression was also elevated in SCLC cell lines compared with the normal bronchial epithelial cell line or NSCLC lines. Moreover, high expression of SBF2-AS1 was associated with clinical stage, tumor size, lymph node metastasis and distant metastasis in SCLC patients. Survival analysis showed SCLC patients with high expression of SBF2-AS1 had shorter overall survival than patients with low expression of SBF2-AS1, and high expression of SBF2-AS1 acted as an independent poor prognostic factor for overall survival in SCLC patients. The study in vitro suggested inhibition of SBF2-AS1 obviously depressed cell proliferation, migration, and invasion in SCLC. In conclusion, SBF2-AS1 acts as a novel oncogenic lncRNA in SCLC. |
| |
| Keywords: | biomarker long noncoding RNAs lung cancer SBF2-AS1 |
|
|
